Bicycle Therapeutics announces leadership transitions

Cambridge, UK-based biotech Bicycle Therapeutics (Nasdaq: BCYC), which is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced leadership transitions for its next phase of innovation.

Dr Michael Method, who began at Bicycle in June 2025 and most recently served as Bicycle’s senior vice president, clinical development, has been promoted to chief medical officer (CMO), overseeing all clinical development and the relationship with Bicycle’s clinical advisory board. Dr Method is an academic and clinical oncologist with extensive drug development experience at many oncology companies, including ImmunoGen and Eli Lilly (NYSE: LLY). Dr Eric Westin, who has retired from his role as CMO, will continue with Bicycle as a distinguished fellow.

Travis Thompson, who began at Bicycle in April 2018 and most recently served as Bicycle’s senior vice president and chief accounting officer and previously spent his career at EY in its life sciences practice supporting a broad range of companies of all sizes and stages of development, has been appointed as Bicycle’s chief financial officer (CFO). In this role, Mr Thompson will continue to oversee finance and accounting functions, and now investor relations. Alethia Young, who has stepped down as CFO, will remain with Bicycle in an interim capacity for three months, and will continue as a company advisor.